24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Diabetes
Resources
Basic InformationLatest News
Blame Diabetes: Rates of 2 Nerve Conditions on the RiseElectronic Messaging Intervention Cuts Cardiovascular Risk in T2DMHealth Tip: Preventing Diabetic Foot SoresEarly Menopause May Be Tied to Type 2 DiabetesMore Than 100 Million Americans Have Diabetes or Prediabetes: CDCNT-proBNP Improves Heart Failure Prediction in T2DMStem Cell Educator Therapy May Help Fight DiabetesResistance Training Improves Microvascular Blood Flow in T2DMNew Diabetes Treatment Teaches Rogue Immune Cells to BehaveIncreased Parental Anxiety With Increased Diabetes RiskIntensive Lifestyle Changes May Up Frailty Fracture Risk in DMExercising Safely With DiabetesHyperbaric Oxygen Therapy Increasingly Being UsedTherapeutic Inertia in 19 Percent With T2DM, HbA1c ≥8 PercentT1DM Patients With Active β-Cell Function Differ ImmunologicallyMany People With Type 1 Diabetes Still Make Some InsulinTryptophan May Be Marker for Diabetic NephropathyEstimated Prevalence of Diabetes 10.9 Percent in ChinaReview Spotlights Optimal Care of T2DM + OsteoporosissRAGE Linked to Risk of Incident Diabetic NephropathyDiabetic Ketoacidosis Poses Fetal Risk During/After EventFDA Warns Diabetics Against Use of Secondhand Test StripsRisk of Cardiovascular Events Similar With, Without DiabetesPCSK9 Increased in Females, Youth With Type 1 DiabetesText Messaging Intervention Can Up Glycemic Control in T2DMGood Results for Zone MPC-Based Artificial PancreasBroccoli Extract Shows Promise for Type 2 DiabetesSleep Apnea Linked to Diabetic Retinopathy in Type 2 DiabetesADA: Canagliflozin Tied to Lower Risk of Cardiovascular EventsKey Diabetes Test Gives Higher Blood Sugar Readings in Black PatientsFor Diabetics, Nasal Powder Fixed Severe Low Blood SugarADA: Glucose Self-Monitoring Often Lacks Benefit in T2DMCan Folks With Type 2 Diabetes Forgo the Finger Stick?Sitagliptin Stimulates Distal Tubular Natriuresis in T2DMStudy Confirms Link Between Diabetes Med and Rare But Dangerous ComplicationLower HbA1c Linked to Better Diabetes-Specific HRQoL in YouthHealth Tip: What's My Target Blood Glucose?Comorbid Celiac Disease Common Among Youth With T1DMDiabetic Foot Ulcers, Infections Significantly Up Burden of CareMapping IDs Geographic Access Barriers for Diabetic RetinopathyNormal Meal Tolerance Test Is Practical, Reliable in T2DMNo Link to Cognition in Diabetes Prevention Program StudySuicide by Insulin?Promising Start for National Diabetes Prevention ProgramDiabetes Drug Gets FDA Warning Due to Amputation RiskAngela Bassett Puts the Spotlight on Heart HealthAs Temps Rise, Risk of Pregnancy Complication May TooPharmacist-Involved Collaborative Care Benefits T2DMNever Breastfeeding Linked to Increased Risk of T1DMBioengineered Intraabdominal Endocrine Pancreas Feasible
Links
Related Topics

Medical Disorders

Fast-Acting Insulin Aspart Ups Glycemic Control in T1DM


HealthDay News
Updated: Apr 14th 2017

new article illustration

FRIDAY, April 14, 2017 (HealthDay News) -- Fast-acting insulin aspart improves glycemic control in type 1 diabetes, according to a study published online April 11 in Diabetes Care.

David Russell-Jones, M.B.B.S., M.D., from the Royal Surrey Country Hospital in Guildford, U.K., and colleagues examined the efficacy and safety of fast-acting insulin aspart (faster aspart) versus conventional insulin aspart (IAsp) in a multicenter phase 3 trial. Adults with type 1 diabetes were randomized to either double-blind mealtime faster aspart (381 adults), IAsp (380 adults), or open-label postmeal faster aspart (382 adults).

The researchers found that in both treatment groups, hemoglobin A1c (HbA1c) was reduced, and noninferiority to IAsp was confirmed for both mealtime and postmeal faster aspart (estimated treatment difference: mealtime, −0.15 percent; postmeal, 0.04 percent). There was a statistically significant reduction in HbA1c for mealtime faster aspart versus IAsp (P = 0.0003). At one hour and two hours after the meal test, postprandial plasma glucose (PPG) increments were statistically significantly lower with mealtime faster aspart (estimated treatment difference, −1.18 mmol/L and −0.67 mmol/L, respectively); for the two-hour PPG increment, superiority to IAsp was confirmed. Between treatments, the overall rate of severe or blood glucose-confirmed hypoglycemic episodes and safety profiles were similar.

"Faster aspart effectively improved HbA1c, and noninferiority to IAsp was confirmed, with superior PPG control for mealtime faster aspart versus IAsp," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novo Nordisk, which funded the study.

Abstract/Full Text (subscription or payment may be required)